A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.
The best Bull and Bear pitches based on recency and number of recommendations.
I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully convinced CYTR is a double bagger at the very least, and more likely a triple when the final… More
Mail some pirates a treasure map leading to the exact spot where you need a hole dug for a tree.
Read the most recent pitches from players about CYTR.
Recs
superstar2
(99.05)
Submitted: 7/12/2016 9:56:31 AM :
Start Price:
$4.59
NASDAQ:CYTR Score:
-168.08
Valuation: considering cash on hand, debt, burn rate, etc. -- above .90 cents. Conservative valuation.
Recs
feenix1944
(< 20)
Submitted: 6/28/2014 12:34:12 PM :
Start Price:
$24.90
NASDAQ:CYTR Score:
-190.73
I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully convinced CYTR is a double bagger at the very least, and more likely a triple when the final results of the global trials are in. The CAPS Community seems to agree wholeheartedly, as well as a number of analysts.
One example from Wall St 24/7:
CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. Analysts mean target price for CytRx Corporation (NASDAQ:CYTR) is $11.00 and On Friday shares its shares opened at $4.25 and trading at $4.14.CytRx Corporation (NASDAQ:CYTR) quarterly earnings growth is 134.80%.
Fellow Fools, I rest my case...
Feenix1944
Recs
csims2007
(< 20)
Submitted: 10/24/2013 10:30:23 AM :
Start Price:
$15.90
NASDAQ:CYTR Score:
-212.88
just based on the value of the company it is a great buy at the current price.
Find the members with the highest scoring picks in CYTR.
mansloth (98.90) Score: +339.05
The Score Leader is the player with the highest score across all their picks in CYTR.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| mansloth | 98.90 | 6/14/2010 |
|
3Y | $34.82 | -99.11% | +239.94% | +339.05 | 0 Comment | |
| longtermgrowth09 | < 20 | 8/3/2010 |
|
5Y | $40.32 | -99.23% | +234.01% | +333.25 | 0 Comment | |
| mathan406 | 70.69 | 2/8/2008 |
|
1Y | $82.48 | -99.62% | +192.56% | +292.18 | 0 Comment | |
| trigfish | 68.08 | 8/16/2007 |
|
3M | $123.35 | -99.75% | +182.92% | +282.66 | 0 Comment | |
| betoo2002 | 30.47 | 1/29/2007 |
|
3M | $92.42 | -99.66% | +180.45% | +280.12 | 0 Comment | |
| tcampbellla | 84.76 | 3/27/2007 |
|
5Y | $173.42 | -99.82% | +178.09% | +277.91 | 0 Comment | |
| xds68 | 73.59 | 2/23/2007 |
|
NS | $161.57 | -99.81% | +174.59% | +274.39 | 0 Comment | |
| ffruga61 | 69.52 | 2/22/2007 |
|
3M | $171.95 | -99.82% | +174.00% | +273.82 | 0 Comment | |
| protozoa1 | 88.70 | 2/21/2007 |
|
NS | $198.46 | -99.84% | +173.83% | +273.68 | 0 Comment | |
| jiminica | 75.61 | 2/16/2007 |
|
1Y | $150.23 | -99.79% | +173.78% | +273.58 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
